Antares Pharma Inc

Antares Pharma — Investor Presentation (May 2006)

38 slides from Antares Pharma's investor presentation, May 5, 2006

  1. Slide 1: Analysts & Investors Luncheon

    Strictly Confidential 1 st st Analysts & Investors Luncheon Analysts & Investors Luncheon The Cornell Club, New York The Cornell Club, New York May 4, 2006 May 4, 2006 Amex: AIS Amex: AIS www.antarespharma.com www.antarespharma.com Exhibit 99.3

  2. Slide 2: Agenda

    Antares Pharma, Inc. © 2006 Confidential 2 The platform technologies and their evolution The Antares product pipeline development system Value creation through own clinical development Value creation through partnerships/alliances Anturol ATD (oxybutynin): A “show-case” example Technology proof-of-c

  3. Slide 3: Pharmaceutical Technology Platforms

    Antares Pharma, Inc. © 2006 Confidential 3 EasyTec™ Orally Disintegrating Tablets Fast-Melt Tablet Technologies TecTix™ Transdermal/Topical Technology Eutectics Semisolid Technologies Topical Delivery Technology Local ATD ™ Combination Gels ATD ™ Single Gels Systemic Advanced Transdermal Delivery (

  4. Slide 4: Antares' Platform Technologies and their Evolution

    Antares Pharma, Inc. © 2006 Confidential 4 Antares’ Platform Technologies and their Evolution Research Effort Results in 2006 There is constant on-going research on strengthening our technologies and intellectual properties. Advanced Transdermal Delivery System ATD ™ ATD ™ Permeation Enhancer • Cons

  5. Slide 5: The Focus and Research Aim

    Antares Pharma, Inc. © 2006 Confidential 5 Drug Delivery Target Antares’ Technologies with Benefits Groups a Reason for Being The Focus and Research Aim EasyTec ™ Superior “Flash” Oral Disintegrating Tablets Delivering drugs with reduced side-effects discretely and/or passively is our R&D mission. A

  6. Slide 6: ATD Advanced Transdermal Delivery Technology

    Antares Pharma, Inc. © 2006 Confidential 6 ATD™ Advanced Transdermal Delivery Technology ATD™ Transdermal Gel Technology

  7. Slide 7: ATD Transdermal Gel Technology: What is it?

    Antares Pharma, Inc. © 2006 Confidential 7 Semi-solid formulations containing one or more drugs A hydro-alcoholic vehicle A combination of permeation enhancers Thickening agents A pH regulator What is it? Increases drug partitioning into the skin Increases drug partitioning into the skin Provides su

  8. Slide 8: ATD Platform Illustration: Mode of Action

    Antares Pharma, Inc. © 2006 Confidential 8 The gel is applied onto the skin Ethanol evaporates, the drug concentration increases, forcing penetration. Co-solvents help avoid drug crystallization Penetration enhancers increase skin permeability resulting in drug delivery through the skin The drug is

  9. Slide 9: ATD Platform Summary: Unique Features

    Antares Pharma, Inc. © 2006 Confidential 9 Validate technology with products being reviewed by FDA Most proven versatile transdermal technology (several therapeutic area) Proven delivery efficiency (Bio-E-Gel vs. Estrasorb) Several ATD products with extensive clinical experience High skin tolerabili

  10. Slide 10: ATD Transdermal Gel Intellectual Property Status

    Antares Pharma, Inc. © 2006 Confidential 10 ATD I Core formulation patent Estrogens, Progestins or mixture thereof HRT, contraception PCT 2001 extension to 4 additional therapeutic classes ATD II: Antares/BioSante co - applications Androgens and/or Estrogens or Progestins Hormonal disorders in men a

  11. Slide 11: TecTix Technology for Dermatology Application

    Antares Pharma, Inc. © 2006 Confidential 11 Eutectics Semisolid Technologies TecTix™ Transdermal/Topical Technology TecTix™ Technology for Dermatology Application

  12. Slide 12: TecTix: What is it?

    Antares Pharma, Inc. © 2006 Confidential 12 Melting point depression of active pharmaceutical ingredients (API) by Chemical Fragrance & Flavors Ingredients (CFFI) Versatile technology that is compatible with numerous API’s Alcohol-free Patent-pending Technology What is it? TecTix™ Technology for Der

  13. Slide 13: TecTix Advantages

    Antares Pharma, Inc. © 2006 Confidential 13 CFFI with a long and safe history of use in perfumes and cosmetics High thermodynamic activity; high concentration of the API in the eutectic mixture (up to 90% w/w) Increase of lipophilic properties increased solubility in lipid membranes Higher dissoluti

  14. Slide 14: Fast Melt Tablets: EasyTec

    Antares Pharma, Inc. © 2006 Confidential 14 Fast Melt Tablets Easy Tec™ Orally Disintegrating Tablet Technology

  15. Slide 15: EasyTec ODT: What is it?

    Antares Pharma, Inc. © 2006 Confidential 15 - Hygroscopic disintegrant(s) - Water-soluble components - Large surface area (high porosity) - Large amount of disintegrants BUT leads to soft, friable, moisture-sensitive tablets BUT leads to low drug loading / large tablets The ideal ODT technology shal

  16. Slide 16: EasyTec Orally Disintegrating Tablet Technology

    Antares Pharma, Inc. © 2006 Confidential 16 Easy Tec™ Orally Disintegrating Tablet Technology

  17. Slide 17: EasyTec Advantages

    Antares Pharma, Inc. © 2006 Confidential 17 Simple, cost-effective direct compression technology Patented technology, new application filed recently Use of a type-C polymethacrylate coating polymer as the primary disintegrating agent Superior palatability Robust tablets allowing conventional packagi

  18. Slide 18: Anturol: Assets in Late Stage Clinical Development

    Antares Pharma, Inc. © 2006 Confidential 18 Fast onset of thera- peutic activity Decreased incidence of side-effects compared to oral and patch Lower topical/site irritation Accurate, improved once-daily dosing More dose flexibility than patch Clinical Phase Summary Dose proportionality found in the

  19. Slide 19: Anturol Phase II Results: Dose Proportionality

    Antares Pharma, Inc. © 2006 Confidential 19 We are pleased with our plasma profiles. ATD ™ Oxybutynin Gel: Anturol ™ – Phase II Results 0 2 4 6 8 10 0 24 48 72 96 120 144 168 192 216 240 264 288 312 336 360 384 408 432 456 480 504 528 552 576 600 Time (Hours) High Intermediate Low Dose Proportionali

  20. Slide 20: Anturol Phase II Results: DEO and OXY Cavg

    Antares Pharma, Inc. © 2006 Confidential 20 ATD ™ Oxybutynin Gel: Anturol ™ – Phase II Results DEO and OXY C avg (Surrogates of Efficacy) 10.1 4.5 4.2 3.0 4.3 5.4 0.0 10.0 20.0 30.0 40.0 50.0 60.0 70.0 80.0 DITROPAN IR tablet 15mg/d DITROPAN XL tablet 15mg/d OXYTROL patch 36mg ANTUROL gel low dose A

  21. Slide 21: Anturol Market Positioning

    Antares Pharma, Inc. © 2006 Confidential 21 ATD ™ Oxybutynin Gel: Anturol ™ – Market Positioning Our innovative Overactive Bladder product will have… Fast onset of therapeutic activity Decreased incidence of systemic SE Lower incidence of local irritation Once-daily dosing More flexibility and discr

  22. Slide 22: Anturol Overview

    Antares Pharma, Inc. © 2006 Confidential 22 Easy to apply and excellent skin tolerability: anticipated better patient compliance Phase III trial design and dosing confirmed at the FDA meeting Worldwide rights controlled by Antares Pharma US market expected to exceed $3.0 Billion in 2008 Overview R&D

  23. Slide 23: Anturol Development Status

    Antares Pharma, Inc. © 2006 Confidential 23 Formulation development Completed First PK study in human Completed IND filing Completed Phase II study and report Completion in Jan 06 Tech-transfer Completion in Apr 06 End of Phase II meeting Completion in May 06 Anturol ATD™ Gel R&D Assets in Late Stag

  24. Slide 24: Pharma ATD Partnered Products

    Antares Pharma, Inc. © 2006 Confidential 24 Pharma ATD™ Partnered Products Pre-clinical Company not disclosed Dermal field Undisclosed AP-1120 Pre-clinical work is being finalized Phase I planned in 3Q Company not disclosed CNS disorder Undisclosed AP-1117 Phase I/II completed BioSante (NA) Solvay (

  25. Slide 25: Pipeline Development: Women's Health Product

    Antares Pharma, Inc. © 2006 Confidential 25 Rationale – Antares’ ATD™ formulation for a combination contraceptive product with existing active compound will allow improved patient compliance . The transdermal contraceptive market has been a rapidly growing segment of the U.S. contraceptive market. O

  26. Slide 26: Co-Development: Women's Health Product

    Antares Pharma, Inc. © 2006 Confidential 26 Rationale – Antares’ ATD™ formulation for a combination contraceptive product with new active compound will allow improved patient compliance. The U.S. market was worth $2.5 billion in 2005. While oral contraceptives are expected to continue to dominate, p

  27. Slide 27: Market Situation: Women's Health Products

    Antares Pharma, Inc. © 2006 Confidential 27 J&J 22% Sonstige 14% Barr 11% Wyeth 9% Akzo Nobel 9% Schering AG 26% Watson 9% 2005 Global Market Share of Hormonal Contraceptives IMS and Kalorama Estimate Global market for contraceptives was estimated at $5.5 billion in 2005, with Schering AG as the mar

  28. Slide 28: Product Partnering: Bio-E-Gel

    Antares Pharma, Inc. © 2006 Confidential 28 Rationale – Antares’ ATD™ formulation demonstrates lowest effective dose and therapy of choice in treating postmenopausal symptoms. The U.S. and European estradiol market, in treating hot flashes and vaginal atrophy, is worth $1.4 billion. Approximately 54

  29. Slide 29: Product Partnering: Libi-Gel

    Antares Pharma, Inc. © 2006 Confidential 29 Rationale – Antares’ ATD™ formulation demonstrates almost 240% increase in frequency of sexual activity. Presently no approved product in U.S. however P&G’s Intrinsa™ patch can provide basis for approval. 2006 Phase III Targeted by Partner Phase II complet

  30. Slide 30: Product Partnering: CNS Product

    Antares Pharma, Inc. © 2006 Confidential 30 Rationale – Antares’ ATD™ system will benefit the specific CNS population allowing preferred dosing & elimination of first pass metabolism. Since being launched in the U.S., the volume of new prescriptions for oral innovator product has quadrupled resultin

  31. Slide 31: Market Situation: CNS Product

    Antares Pharma, Inc. © 2006 Confidential 31 Targeted Disease Market is Forecasted to Grow to $3.3 Billion. Market Situation - CNS Product

  32. Slide 32: Pipeline Development: CNS Product (AP-1002)

    Antares Pharma, Inc. © 2006 Confidential 32 Rationale for AP-1002 – Antares’ ATD™ system will benefit anxiety / phobia population allowing once daily dosing & elimination of first pass metabolism. Consistent and potentially lower dose release of alprazolam throughout the day, offering patients who s

  33. Slide 33: Market Situation: CNS Product

    Antares Pharma, Inc. © 2006 Confidential 33 U.S. Benzodiazepine Market was approximately $600 million in 2004 Diazepam 14% Lorazepam 20% Clonazepam 16% Temazepam 10% Alprazolam 40% Market Situation - CNS Product

  34. Slide 34: Preclinical Pipeline

    Antares Pharma, Inc. © 2006 Confidential 34 Pharma ATD™ Pharma ATD™ Preclinical Pipeline Preclinical Pipeline Expired Market: $1.6 Bil Oncology AP-1077 Expired Total soft-tissue injury market: $2.5 Bil Rheumatology AP-1100 Expired Market: $2.3 Bil 16% market share Oncology AP-1121 Expired ~5% of pre

  35. Slide 35: Pharma EasyTec Tablet Product: AP-159 ODT Accomplishments

    Antares Pharma, Inc. © 2006 Confidential 35 Formulation development Completed In vitro dissolution test on final prototype Completed April 06 Manufacturing Tech-transfer Completed April 06 AP-159 ODT Accomplishments Pharma Easy Tec™ Tablet Product

  36. Slide 36: Summary of Development Achievements

    Antares Pharma, Inc. © 2006 Confidential 36 Continued to develop new intellectual property for both oral and transdermal platforms. Focused on reduced side-effects while providing discrete and passive delivery. Researched and selected a pipeline of molecules with “blockbuster” potential for clinical

  37. Slide 37: Pharma Business Objectives 2006

    Antares Pharma, Inc. © 2006 Confidential 37 Summary of Objectives Initiation of Phase III clinical study for Anturol ATD™ gel File ANDA for AP-159 Easy Tec™ tablet Identify ex-U.S. partner for Bio-E-Gel Initiation of Phase I for AP-1117 Initiation of Phase I program(s) currently in pre-clinical phas

  38. Slide 38: Strictly

    Strictly Confidential

Antares Pharma — Investor Presentation (May 2006) on 6ix